Company profile RLMD
There is not enough data for Relmada Therapeutics - Esmethadone to provide analysis
There is not enough data for Relmada Therapeutics - Esmethadone to provide correlation calculation
There is not enough data for Relmada Therapeutics - Esmethadone to provide analysis
After 39 days of this quarter the interest is at 166.0. Based on that we can calculate that during remaining 52 days it will total up to 387.0. d-methadone expected interest is significantly higher compared to previous quarter (+200.0%) and same quarter last year (+197.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 21 | 132 528.6% QoQ | 0 -100.0% QoQ | 69 inf% QoQ |
| 2020 | 128 509.5% YoY 85.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 236 inf% YoY inf% QoQ | 45 -34.8% YoY -80.9% QoQ |
| 2021 | 37 -71.1% YoY -17.8% QoQ | 105 inf% YoY 183.8% QoQ | 133 -43.6% YoY 26.7% QoQ | 74 64.4% YoY -44.4% QoQ |
| 2022 | 135 264.9% YoY 82.4% QoQ | 20 -81.0% YoY -85.2% QoQ | 25 -81.2% YoY 25.0% QoQ | 19 -74.3% YoY -24.0% QoQ |
| 2023 | 130 -3.7% YoY 584.2% QoQ | 61 205.0% YoY -53.1% QoQ | 46 84.0% YoY -24.6% QoQ | 129 578.9% YoY 180.4% QoQ |
| 2024 | 166 27.7% YoY 28.7% QoQ | - | - | - |
The average 5 years interest of d-methadone was 6.56 per week. The last year interest of d-methadone compared to the last 5 years has changed by 29.57%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 77.45%.
After 39 days of this quarter the interest is at 46.0. Based on that we can calculate that during remaining 52 days it will total up to 107.0. dextromethadone expected interest is significantly higher compared to previous quarter (+inf%) and same quarter last year (+inf%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 72 | 61 -15.3% QoQ | 242 296.7% QoQ | 195 -19.4% QoQ |
| 2020 | 110 52.8% YoY -43.6% QoQ | 64 4.9% YoY -41.8% QoQ | 189 -21.9% YoY 195.3% QoQ | 49 -74.9% YoY -74.1% QoQ |
| 2021 | 154 40.0% YoY 214.3% QoQ | 221 245.3% YoY 43.5% QoQ | 69 -63.5% YoY -68.8% QoQ | 167 240.8% YoY 142.0% QoQ |
| 2022 | 151 -1.9% YoY -9.6% QoQ | 105 -52.5% YoY -30.5% QoQ | 196 184.1% YoY 86.7% QoQ | 110 -34.1% YoY -43.9% QoQ |
| 2023 | 0 -100.0% YoY -100.0% QoQ | 86 -18.1% YoY inf% QoQ | 87 -55.6% YoY 1.2% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2024 | 46 inf% YoY inf% QoQ | - | - | - |
The average 5 years interest of dextromethadone was 9.1 per week. The last year interest of dextromethadone compared to the last 5 years has changed by -53.74%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -64.53%.
After 39 days of this quarter the interest is at 151.0. Based on that we can calculate that during remaining 52 days it will total up to 352.0. REL-1017 expected interest is significantly higher compared to previous quarter (+851.4%) and same quarter last year (+458.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 34 | 97 185.3% QoQ | 155 59.8% QoQ | 83 -46.5% QoQ |
| 2020 | 46 35.3% YoY -44.6% QoQ | 63 -35.1% YoY 37.0% QoQ | 30 -80.6% YoY -52.4% QoQ | 38 -54.2% YoY 26.7% QoQ |
| 2021 | 137 197.8% YoY 260.5% QoQ | 228 261.9% YoY 66.4% QoQ | 176 486.7% YoY -22.8% QoQ | 127 234.2% YoY -27.8% QoQ |
| 2022 | 66 -51.8% YoY -48.0% QoQ | 73 -68.0% YoY 10.6% QoQ | 112 -36.4% YoY 53.4% QoQ | 185 45.7% YoY 65.2% QoQ |
| 2023 | 63 -4.5% YoY -65.9% QoQ | 111 52.1% YoY 76.2% QoQ | 24 -78.6% YoY -78.4% QoQ | 37 -80.0% YoY 54.2% QoQ |
| 2024 | 151 139.7% YoY 308.1% QoQ | - | - | - |
The average 5 years interest of REL-1017 was 7.8 per week. The last year interest of REL-1017 compared to the last 5 years has changed by -4.87%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 4.51%.
After 39 days of this quarter the interest is at 112.0. Based on that we can calculate that during remaining 52 days it will total up to 261.0. major depressive disorder treatment expected interest is significantly lower compared to previous quarter (-63.3%) and same quarter last year (-49.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 257 | 265 3.1% QoQ | 216 -18.5% QoQ | 319 47.7% QoQ |
| 2020 | 284 10.5% YoY -11.0% QoQ | 322 21.5% YoY 13.4% QoQ | 186 -13.9% YoY -42.2% QoQ | 430 34.8% YoY 131.2% QoQ |
| 2021 | 367 29.2% YoY -14.7% QoQ | 327 1.6% YoY -10.9% QoQ | 253 36.0% YoY -22.6% QoQ | 389 -9.5% YoY 53.8% QoQ |
| 2022 | 507 38.1% YoY 30.3% QoQ | 591 80.7% YoY 16.6% QoQ | 307 21.3% YoY -48.1% QoQ | 612 57.3% YoY 99.3% QoQ |
| 2023 | 514 1.4% YoY -16.0% QoQ | 604 2.2% YoY 17.5% QoQ | 382 24.4% YoY -36.8% QoQ | 712 16.3% YoY 86.4% QoQ |
| 2024 | 112 -78.2% YoY -84.3% QoQ | - | - | - |
The average 5 years interest of major depressive disorder treatment was 30.48 per week. The last year interest of major depressive disorder treatment compared to the last 5 years has changed by 35.14%. The interest for major depressive disorder treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 89.38%.
There is not enough data for CNS diseases treatment to provide analysis
There is not enough data for CNS diseases treatment to provide correlation calculation
There is not enough data for CNS diseases treatment to provide analysis
There is not enough data for N-methyl-D-aspartate receptor antagonist to provide analysis
There is not enough data for N-methyl-D-aspartate receptor antagonist to provide correlation calculation
There is not enough data for N-methyl-D-aspartate receptor antagonist to provide analysis
There is not enough data for clinical-stage biotechnology company to provide analysis
There is not enough data for clinical-stage biotechnology company to provide correlation calculation
There is not enough data for clinical-stage biotechnology company to provide analysis